What factors drove the changes in Humana's revenue and profit?

What does Humana do and what are its main business segments?

What guidance did Humana's management provide for the next earnings period?

What is the market's earnings forecast for Humana next quarter?

Did Humana beat or miss consensus estimates last quarter?

What is the revenue and EPS growth rate for Humana year over year?

What is Humana's gross profit margin?

What is Humana's latest dividend and current dividend yield?

- **Membership Surge**: 1 million new members (20% growth) driven by switchers and bounce-backs, with 70% in 4+ Star plans.
- **Margin Challenge**: 2026 MA margin slightly below breakeven due to $3.5B Stars headwind, but doubling when normalized.
- **Operational Strength**: Reduced Medicare complaints and improved service scores despite 25% membership growth.
- **Stars Recovery**: Early progress toward 2028 Top Quartile goal, with focus on proactive member onboarding.
- **Capital Efficiency**: <20% capital growth vs. 40% premium growth, funded by optimization and M&A.

**【CEO Summary Section】**
- **Membership Growth**: Achieved 1 million new members (20% growth) in AEP 2025, with 70% of new sales from competitor switchers and 30% bounce-back members. Retention rate improved by 500 basis points YoY.
- **Margin Focus**: Committed to a stable and compelling Medicare Advantage (MA) margin, with 2026 individual MA margin expected to be slightly below breakeven due to $3.5 billion Stars headwind.
- **Operational Capacity**: Confident in ability to onboard new members without compromising quality, evidenced by reduced Medicare complaints and improved Net Promoter Scores.
- **Stars Strategy**: Aiming to return to Top Quartile Stars performance by 2028, with early indicators (e.g., health risk assessments, complaints) showing progress despite headwinds.
- **2028 Vision**: Reaffirmed goal to unlock earnings potential by 2028, with 2026 serving as a stepping stone for margin improvement and operational efficiency.

**【CFO Financial Commentary】**
- **2025 Performance**: Adjusted EPS of $17.14, in line with expectations, driven by solid Insurance and CenterWell segment performance.
- **2026 Guidance**: Full-year adjusted EPS of at least $9, with individual MA margin doubling (normalizing for Stars). Stars headwind of $3.5 billion includes 45% of members in 4+ Star plans and higher retention of 3.5-star contracts.
- **Cost Efficiency**: Operating cost ratio improvement due to membership growth, tactical cost-cutting (e.g., early retirement program), and multiyear transformation initiatives (e.g., outsourcing, automation).
- **Capital Management**: Statutory capital requirements to increase <20% YoY, funded by premium growth and capital optimization. Debt-to-capital ratio expected to remain stable, supporting M&A and strategic investments.

**【Q&A Highlights】**
- **Margin Progression**: New members expected to contribute to margin improvement over 3-5 years, with marketing load declining and MLR normalization. Existing members face higher Stars-related costs but show early signs of medical management improvement.
- **Stars Risk Mitigation**: Proactive onboarding programs (e.g., health risk assessments) and earlier implementation of value-based care reduce Stars variability. 75th percentile Stars target provides flexibility vs. absolute Star ratings.
- **Rate Notice Impact**: ARN below medical cost trend highlights funding environment challenges, but company will adapt benefits and pricing to maintain margin sustainability.
- **Value-Based Care**: ~1/3 of MA members in capitated or value-based arrangements, with partnerships focused on reducing friction and improving provider payment efficiency.
- **Investment Strategy**: 2025 incremental investments (~$550M) focused on medical costs and transformation; 2026 spending will balance short-term performance with long-term efficiency.

Humana Inc. (HUM) Q4 2025 Earnings Call Transcript

- **MA Growth Strategy**: Prioritizes retention over new sales, with channel mix focused on high-value segments. Stars recovery progress visible in '28, though '27 results disappointing.
- **Financial Discipline**: $17 EPS target reaffirmed despite $150M investments. Capital allocation balanced between M&A and debt management.
- **Key Metrics**: Reduced plan-to-plan sales (down YoY), 600K+ gaps closed in '28, and DCP timing-driven changes highlight operational focus.
- **Long-Term Vision**: Shift to LTV/Stars-driven margin, with 2026 MA margin doubling 2025 levels if Stars thresholds align.

**【CEO Summary Section】**
- **Medicare Advantage (MA) Growth Strategy**: Emphasized focus on retention over new sales, with new sales at the high end of expectations. Retention rates are a key metric, with reduced plan-to-plan sales (down year-over-year), indicating better member stability. However, specific growth targets are withheld due to operational capacity concerns.
- **Channel Mix Optimization**: Greater volume in high-performing partner and digital channels, which correlate with higher lifetime value. Avoiding outsized sales in low-margin plans to maintain operational efficiency.
- **Stars Program Recovery**: Bonus Year '27 results were disappointing but consistent with expectations. Bonus Year '28 shows early operational progress, with 600,000 more gaps closed year-over-year, though final results depend on thresholds.
- **Long-Term Value (LTV) Framework**: Shift to lifetime value and NPV as primary metrics, balancing short-term margin with long-term sustainability. Avoiding the cycle of low-margin, high-growth products.

**【CFO Financial Commentary】**
- **Third-Quarter Performance**: Solid execution with medical cost trends in line with expectations. Reaffirmed full-year adjusted EPS outlook of $17, despite incremental investments ($150 million) in Stars and network management.
- **Capital Allocation**: Proceeding with non-core asset sales (e.g., Enclara Pharmacia) and M&A (e.g., Villages Health). Debt-to-cap ratio at 40.3%, targeting ~40% long-term. Share buybacks offset dilution from stock-based compensation.
- **Balance Sheet Management**: DCP metric reflects timing variations, not reserve levels. IBNR consistency supports claims reserve strength, despite individual MA membership decline.

**【Q&A Highlights】**
- **Membership Growth Dynamics**: New sales at the high end of expectations, but operational capacity limits transparency on exact numbers. Focus on channel mix (e.g., digital, high-performing partners) to mitigate risk.
- **Stars Mitigation Efforts**: Proactive measures with providers, including contract changes and Stars mitigation programs. Progress in 2026 will depend on provider partnerships and Stars thresholds.
- **2026 Outlook**: MA margin expected to double 2025 levels, driven by product design and channel mix. However, final results hinge on Stars performance and operational execution.
- **Market Trends**: CMS forecasts suggest mid-single-digit MA growth, consistent with historical patterns. Humana remains below or at parity with competitors in key geographies, limiting fee-for-service attrition risk.

Humana Inc. (HUM) Q3 2025 Earnings Call Transcript

- **EPS Upgrade to $17**: Driven by CenterWell Pharmacy outperformance and better-than-expected MA membership retention.
- **Operational Efficiency Push**: $100M investments in AI, member retention, and back office transformation to drive long-term margin stability.
- **Medicaid Expansion Success**: 10 active contracts with focus on LTSS, less impacted by regulatory changes.
- **Stars Litigation Update**: Refiled case; operational focus on improving quality metrics for BY '27/28.
- **Sustainable Growth**: CenterWell Pharmacy direct-to-consumer and Specialty Pharmacy mix driving year-to-date outperformance.

**【CEO Summary Section】**
- **EPS Outlook Raised**: Full-year 2025 EPS increased to $17 from $16.25, driven by better-than-expected performance in CenterWell Pharmacy and individual MA membership retention.
- **Four Key Drivers**: 
  1. **MA Product & Experience**: Membership decline of 500,000 vs. 550,000 prior guidance, with bounce-back members (returning from other plans) improving year-1 economics.
  2. **Clinical Excellence**: Focused on Stars ratings (BY '27 and '28), with ongoing operational progress despite legal challenges.
  3. **Back Office Efficiency**: Early retirement program and outsourcing initiatives to streamline costs and enable multiyear transformation.
  4. **Capital Allocation**: Strategic growth in Medicaid (10 states active) and CenterWell Pharmacy, with Virginia Medicaid launch.
- **CenterWell Outperformance**: Direct-to-consumer volume and Specialty Pharmacy mix favorability drove year-to-date growth.

**【CFO Financial Commentary】**
- **Q2 Results**: GAAP net income $420M, Non-GAAP EPS $1.08 (vs. expectations). Medical cost trends in line with guidance.
- **Incremental Investments**: $100M in member retention, AI, and operational efficiency, focusing on high-return initiatives.
- **Capital Deployment**: $100M share buybacks to offset dilution; $200M debt buyback using bond issuance proceeds. Long-term focus on accretive M&A and dividend growth.

**【Q&A Key Highlights】**
- **Medicaid Performance**: Outperformed peers due to focus on LTSS (long-term support services) in non-expansion states, with 10 active contracts and 3 pending.
- **Part D Trends**: Rx trends in line with expectations, with no unexpected behavioral changes. 2026 bids reflect CMS rule adjustments.
- **Stars Litigation**: Refiled case post-appeals; operational focus on BY '27/28 quality metrics despite legal uncertainty.
- **Home Health Rules**: Proposed 6%+ rate reduction challenges, but natural hedge via Insurance business and enterprise-level mitigation.
- **Membership Growth**: Confident in ability to absorb growth without compromising margins, with focus on product richness and member experience.

Humana Inc. (HUM) Q2 2025 Earnings Call Transcript

- **Q1 Strong Start**: Exceeded expectations with stable Medicare growth, 25% care gap reduction, and AI-driven 30% call time reduction.
- **CenterWell Momentum**: 30 new centers added, 175K-250K Medicaid growth, and 30% ER visit reduction through integrated care.
- **Stars Uncertainty**: 3%+ MA margin target hinges on unresolved Star ratings litigation.
- **Medicaid Expansion**: 13-state footprint with Virginia on track, Illinois dual-eligible win, and improving margins.
- **V28 Resilience**: J-curve maturity unaffected; 160bps 2025 impact tracked as expected with no structural care model impairment.

**【CEO Opening Remarks】**
- Q1 2025 performance exceeded expectations, with reaffirmed full-year guidance. Key highlights include:
  - Medicare membership growth remained stable, with positive trends post Open Enrollment Period (OEP).
  - Clinical excellence initiatives drove a 25% year-over-year reduction in care gaps through virtual and in-person health programs.
  - G&A costs were slightly better than expected, supported by AI adoption in contact centers reducing call times by 30%.
  - CenterWell added 30 new primary care centers, fueling 175,000-250,000 Medicaid patient growth and winning Illinois' dual-eligible special needs program.

**【CFO Financial Highlights】**
- Adjusted EPS of $16.25 for 2025, driven by:
  - Insurance segment benefit ratio of 90.1%-90.5%, reflecting strong medical cost trend management.
  - Non-GAAP EPS outperformance due to delayed Star-related investments (10bps in Q1, higher in Q2-4).
  - Cost efficiencies from balance sheet optimization and AI-driven operational improvements.

**【Q&A Key Takeaways】**
1. **Stars Litigation & MA Margin Target**: 
   - 3%+ MA margin target remains unchanged, contingent on Star ratings resolution.
   - 2026 Star bid strategy focuses on diversification and long-term margin sustainability.
2. **CenterWell Performance**: 
   - Primary care patient growth exceeded expectations, with 30% reduction in ER visits through integrated care.
   - Pharmacy specialty drug mix favorability contributed to Q1 outperformance.
3. **Medicaid Expansion**: 
   - 13-state footprint expansion, including Virginia implementation and Illinois dual-eligible wins.
   - Margins improving as rates align with recent trend experience.
4. **V28 Mitigation**: 
   - J-curve maturity unaffected; V28 impact (160bps in 2025) tracked as expected, with no structural impairment to value-based care models.


Humana (HUM)-30 Apr 25-2025 Q1 Earnings call transcript

- **2024 Financial Resilience**: Adjusted EPS met expectations despite headwinds, setting a 3%+ MA margin target for 2025.
- **Stars Recovery Focus**: 650K care gaps closed in Q4 2024, with full operational runway for 2028 Stars rebound.
- **Medicaid Growth Tradeoff**: 2025 Medicaid expansion (175K-250K members) expected to drag margins, but positioning for long-term value.
- **Part D Shifts**: 60-65% of 2025 earnings front-loaded due to IRA changes, requiring agile claims management.
- **Litigation Risk**: 2026 Stars outcome uncertain, with no mitigation plan yet for potential adverse ruling.

**【CEO Opening Remarks】**
- **2024 Performance**: Adjusted EPS in line with initial guidance, despite investments in Stars and growth. 2025 outlook reaffirmed, targeting at least 3% margin in individual MA.
- **New Leadership**: Introduced Celeste Mellet (CFO), Michelle O'Hara (Chief HR Officer), and Japan Mehta (Chief Information Officer) to drive innovation and efficiency.
- **Four Growth Levers**:
  1. **Product Experience**: 5% membership growth in 2024, focusing on shedding unprofitable plans and improving member mix.
  2. **Clinical Excellence**: Closed 650,000 care gaps in Q4 2024, aiming for Stars recovery by 2028.
  3. **Operational Efficiency**: Improved operating expense ratio by 40bps in 2024 through cost optimization.
  4. **Capital Allocation**: Balancing margin recovery with strategic growth in CenterWell and Medicaid.

**【CFO Financial Update】**
- **MLR Guidance**: 2025 MLR increase driven by Medicaid growth, IRA impacts, and Stars investments. Offsets include plan exits and benefit adjustments.
- **Cost Management**: 2024 operating expense ratio improved by 40bps, with further efficiency initiatives planned.
- **Medicaid Expansion**: 175,000-250,000 member growth in 2025, targeting long-term margin recovery despite near-term drag.

**【Q&A Highlights】**
- **Stars Litigation**: 2026 outcome uncertain; focus on operational improvements for 2028 Stars recovery.
- **D-SNP Attrition**: 30,000 losses due to redeterminations, but strategic shifts to higher-value segments.
- **Part D Seasonality**: 60-65% of 2025 earnings expected in Q1 due to IRA changes and deductible design.
- **Group MA Margin**: Pressure in 2025 from long-term contracts, with margin improvement expected in 2026.
- **Mitigation Strategy**: No decision yet on cross-walking group contracts if Stars appeal fails.


Actual																5.4	12.56	3.08	-2.3	7.67	6.89	4.83	1.24	8.04	8.67	6.88	1.62	9.38	8.94	7.78	-0.11	7.23	6.96	4.16	-2.16	11.58	6.27	3.24	-3.96
Forecast																4.6649	10.2717	2.8125	-2.3688	7.0744	6.8252	4.6752	1.1572	6.8003	7.6662	6.2764	1.461	9.2703	8.7579	7.1627	0.8073	6.1186	5.864	3.4189	-2.2311	10.072	5.9176	2.926	-4.002
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	+15.76%	+22.28%	+9.51%	+2.90%	+8.42%	+0.95%	+3.31%	+7.16%	+18.23%	+13.09%	+9.62%	+10.88%	+1.18%	+2.08%	+8.62%	-113.63%	+18.16%	+18.69%	+21.68%	+3.19%	+14.97%	+5.96%	+10.73%	+1.05%

Actual	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	18.93B	19.08B	20.07B	19.06B	20.67B	20.64B	20.87B	21.05B	23.97B	23.66B	22.80B	22.44B	26.74B	26.75B	26.42B	26.46B	29.61B	29.54B	29.40B	29.21B	32.11B	32.39B	32.65B	32.52B
Forecast	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	18.45B	18.64B	18.62B	18.77B	20.48B	20.51B	20.90B	21.22B	23.54B	23.45B	22.82B	22.48B	26.43B	25.83B	25.57B	25.51B	28.52B	28.52B	28.68B	28.81B	32.20B	31.87B	32.00B	32.04B
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	+2.62%	+2.39%	+7.81%	+1.56%	+0.94%	+0.67%	-0.16%	-0.78%	+1.85%	+0.92%	-0.07%	-0.18%	+1.19%	+3.57%	+3.33%	+3.72%	+3.81%	+3.56%	+2.50%	+1.40%	-0.27%	+1.62%	+2.04%	+1.47%

HUM

HUM fundamentals

HUM Q4 2025 Earnings

Earnings Call

You can ask Aime

HUM

HUM fundamentals

HUM Q4 2025 Earnings

Earnings Call

HUM Earnings Call Summary for Q4/20258:00 AM on Feb 11, 2026

HUM Earnings Call Summary for Q3/20258:00 AM on Nov 5, 2025

HUM Earnings Call Summary for Q2/20258:00 AM on Jul 30, 2025

HUM Earnings Call Summary for Q1/20258:00 AM on Apr 30, 2025

HUM Earnings Call Summary for Q4/20249:00 AM on Feb 11, 2025

You can ask Aime